Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Nozza

Showing results (81-90 of 175) with videos related to

Pageof 18
Sort By:
The Journal of Antimicrobial Chemotherapy|June 9, 2012
Immune recovery and T cell subset analysis during effective treatment with maravirocFrancesca Cossarini, Andrea Galli, Laura Galli, et al.
AIDS (London, England)|April 8, 2021
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimenNicola Gianotti, Laura Galli, Andrea Poli, et al.
Vaccine|October 11, 2025
Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infectionAngelo Roberto Raccagni, Giulia Morsica, Pierluigi Reali, et al.
BMJ Open|January 5, 2023
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohortSilvia Nozza, Angelo Roberto Raccagni, Riccardo Lolatto, et al.
AIDS (London, England)|February 16, 2010
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experienceSilvia Nozza, Laura Galli, Francesca Visco, et al.
AIDS (London, England)|February 26, 2025
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimensMichele Bellomo, Nicola Gianotti, Hamid Hasson, et al.
Viruses|March 30, 2023
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical CharacteristicsCaterina Candela, Angelo Roberto Raccagni, Elena Bruzzesi, et al.
Expert Review of Respiratory Medicine|May 29, 2026
Individualized TB care for drug-susceptible pulmonary tuberculosis: clinical alternatives when HRZE is contraindicated or not toleratedLucia Allavena, Jessica Mencarini, Giovanni Fumagalli, et al.
The New Microbiologica|October 6, 2016
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR StudySilvia Nozza, Angela Rosa Pignataro, Laura Galli, et al.
AIDS (London, England)|July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety resultsAntonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
Pageof 18

Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
The Journal of Antimicrobial Chemotherapy|June 9, 2012
Immune recovery and T cell subset analysis during effective treatment with maravirocFrancesca Cossarini, Andrea Galli, Laura Galli, et al.
AIDS (London, England)|April 8, 2021
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimenNicola Gianotti, Laura Galli, Andrea Poli, et al.
Vaccine|October 11, 2025
Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infectionAngelo Roberto Raccagni, Giulia Morsica, Pierluigi Reali, et al.
BMJ Open|January 5, 2023
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohortSilvia Nozza, Angelo Roberto Raccagni, Riccardo Lolatto, et al.
AIDS (London, England)|February 16, 2010
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experienceSilvia Nozza, Laura Galli, Francesca Visco, et al.
AIDS (London, England)|February 26, 2025
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimensMichele Bellomo, Nicola Gianotti, Hamid Hasson, et al.
Viruses|March 30, 2023
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical CharacteristicsCaterina Candela, Angelo Roberto Raccagni, Elena Bruzzesi, et al.
Expert Review of Respiratory Medicine|May 29, 2026
Individualized TB care for drug-susceptible pulmonary tuberculosis: clinical alternatives when HRZE is contraindicated or not toleratedLucia Allavena, Jessica Mencarini, Giovanni Fumagalli, et al.
The New Microbiologica|October 6, 2016
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR StudySilvia Nozza, Angela Rosa Pignataro, Laura Galli, et al.
AIDS (London, England)|July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety resultsAntonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
Pageof 18